Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20230905059361N1
IRCT20230905059361N1
Recruiting
Phase 3

Evaluation of the effects of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson: A randomized double blind trial

Shahre-kord University of Medical Sciences0 sites62 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsParkinson disease.Parkinson's disease

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Parkinson disease.
Sponsor
Shahre-kord University of Medical Sciences
Enrollment
62
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shahre-kord University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Known Parkinson's disease
  • •presence of Parkinson's symptoms in the patient
  • •The symptoms are not due to other diseases (such as stroke, trauma, etc.)
  • •No interaction with other drugs
  • •No history of seizures

Exclusion Criteria

  • •Reluctance to cooperate
  • •Interference of the intervention drug with usual drugs
  • •Aggravation of the patient's symptoms
  • •History or occurrence of seizures

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
In-vivo Bioequivalence Test Fampridine tablet with brand drug FAMPYRA Made by Biogen Idec, UK.The aim of this study is evaluation of bioequivalence of test and reference drugs and the study will one by healthy volunteers.
IRCT20200105046010N19Pharan shimi Pharmaceutical Company24
Recruiting
Phase 3
Evaluating the short-term effect of Fampridine on cognitive function in Multiple sclerosis patients
IRCT20161212031362N4Iranian Center of Neurological Research108
Recruiting
Phase 3
The effect of famotidine on reducing the side effects of prostate cancer radiotherapy
IRCT20231121060132N1Kermanshah University of Medical Sciences50
Recruiting
Phase 3
Dalfampridine in improving spasticity in patients with severe brain traumaSevere traumatic brain injury.Diffuse traumatic brain injuryS06.2
IRCT20221108056446N2Esfahan University of Medical Sciences80
Completed
Phase 4
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MSSecondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
NCT02208050University College Dublin64